The Dendrogenix team has been built on complementary and multidisciplinary backgrounds and skills.
Emile LORIA, MD
Co-founder and Chairman
Emile Loria (MD) is co-founder and Chairman of the Board at Dendrogenix SA. Previously, he was a researcher in the cancer institute in Villejuif and then in the Cancer and Immunogenetics Institute (INSERM-CNRS) founded by professor Georges Mathe. In 1986, he founded MS Medical Synergy, a company that specializes in drug management. Emile Loria is also co-founder of OSE Immunotherapeutics. He has more than 25 years of experience in the pharmaceutical and biotechnology sectors, occupying key positions, in particular with Portable Genomics, Biovector, Ciba-Geigy, IDM Pharma, Epimmune and Sanofi Pharma.
Chief Executive Officer
With more than 25 years of experience in management positions in the biotechnological industry, Stéphane already has to his credit, as an inventor and entrepreneur, a "success story" relating to the development of a breakthrough technology in the food industry, generating several patents and ceded at multinational Nestlé. In 2002, Stéphane Silvente founded and led as Chairman and CEO Affichem SA, a biotech company which develops drug candidates in oncology neurology and dermocosmetics fields. In 2018, Stéphane is appointed CEO of Dendrogenix SA, a biotech company in neurodegenerative and cancer therapy areas. Stéphane Silvente is graduated from the EDC Paris Business School, a DESS "Trilingual Negotiator of International Trade" from the University of Valenciennes, a Master's degree (MBA in Innovation Marketing and Food Transfer) at Toulouse Business School.
Director of Finance and Administration
With more than 19 years experienced, Frédéric Thivet has obtained skills in legal, human resources, management and finances fields. He has previously occupied positions in law firms and several companies. Lately, as Director of Finance and Administration of Affichem, he has spent more than 14 years in an executive position in the field of biotechnology companies. Frédéric Thivet is graduated from the University of Toulouse with a university degree in Economic and Social Administration and a Masters degree in Private Law with a distinction in Business Law and from the Toulouse School of Management with an MBA.
Arnaud RIVES, PhD
Arnaud Rives was in charge of setting up and managing Affichem's medicinal chemistry laboratory. With about 10 years of experience in multi-step synthesis and implementation of optimization processes for the production of bioactive molecules, Arnaud was appointed Project Manager in chemistry at Dendrogenix. Arnaud has been developing optimized chemical syntheses for the different families of Dendrogenins for five years and has a unique expertise in this type of specialty chemistry. He got a PhD in Chemistry-Biology-Health specialty chemistry at the University of Toulouse in 2010.
Nicolas CARON, PhD
Nicolas Caron has acquired a varied experience at Affichem, and has a unique and valuable know-how for innovative research. After successfully conducting these various missions, Nicolas was appointed Project Manager and he oversaw European projects such as AFHELO and TARGEAR. Nicolas has been an integral part of the structure since its creation, and the combination of his talents and skills has contributed to the development of the company. It is the privileged link between the R & D and corporate activities in the company, as well as with regional partners. He got a PhD in Biomedical and Pharmaceutical Science at the University of Liège in the team of Prof. B. Malgrange (Chairman of SAB) in 2014.
Quentin MARLIER, PhD
Assistant Project manager
After obtained his PhD in Biomedical and Pharmaceutical Science at the University of Liège in the team of Prof. B. Malgrange in 2018, he has completed a thesis on cell cycle dysregulation in central nervous system pathologies and he was appointed Assistant Project Manager in october 2018.
Pierre ATTALI, MD
Doctor, MSc, specialist in gastroenterology, Pierre Attali has more than 30 years of experience in global R&D management positions in the pharmaceutical industry (Synthelabo, Sanofi) and biotechnology companies (BioAlliance Pharma, Onxeo, Sensorion). He also has accompanied the development, registration and commercialization in Europe and the USA of more than 10 new molecules or formulations. He has contributed to the publication of more than 100 articles in peer-reviewed journals, oral and poster presentations, and patent filings.